Effects of tripterygium glycosides on restenosis following endovascular treatment

Han,Bing; Ge,Chang‑Qing; Zhang,Hong‑Guang; Zhou,Chen‑Guang; Ji,Guo‑Hui; Yang,Zheng; Zhang,Liang

doi:10.3892/mmr.2016.5149

Effects of tripterygium glycosides on restenosis following endovascular treatment

Authors:
- Bing Han
- Chang‑Qing Ge
- Hong‑Guang Zhang
- Chen‑Guang Zhou
- Guo‑Hui Ji
- Zheng Yang
- Liang Zhang
View Affiliations

Affiliations: Department of Vascular Surgery, The Second Hospital of Baoding, Baoding, Hebei 071051, P.R. China
Published online on: April 20, 2016 https://doi.org/10.3892/mmr.2016.5149
Pages: 4959-4968
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mechanism and associated factors of restenosis following intravascular stent implantation remain to be elucidated. The present two‑part experimental and clinical study aimed to investigate the effects of tripterygium glycosides on in‑stent restenosis subsequent to intra‑arterial therapy. Following endovascular stent implantation in rabbit iliac arteries, post‑stent outcomes were evaluated in cyclosporine groups, low‑dose and high‑dose tripterygium glycosides groups and controls. Post‑operative angiography indicated that vessel diameters were similar between groups; however, at 28 days after receiving the therapeutic agents, vessels of the cyclosporine and tripterygium glycosides groups were significantly larger than those of the controls. Furthermore, three groups of patients had comparable baseline levels of interleukin (IL)‑10, IL‑18 and C‑reactive protein, and intima‑media thickness. However, 1 month after stent implantation, levels of IL‑10 and IL‑18 were markedly reduced in the high‑ and low‑dose tripterygium glycosides groups compared with controls. At 6 months after surgery, the stent patency rate in patients with bare stents was significantly lower than in patients receiving tripterygium glycosides (P≤0.009). In addition, the ankle‑brachial index was also higher than in those without tripterygium glycosides (P<0.001). Results of the experimental and clinical studies suggest that tripterygium glycosides may inhibit and possibly aid in the prevention of in‑stent restenosis formation following endovascular treatment of lower‑extremity artery disease.

View Figures

View References

1	Xu N, Zhang J, Li M, Pan J and Lu Z: Incidence and classification of neointimal proliferation and in-stent restenosis in post-stenting patients at 1-year interval: Findings from non-invasive coronary computed tomography angiography. Eur J Radiol. 83:1816–1821. 2014. View Article : Google Scholar : PubMed/NCBI
2	Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Miekusch W, Schlager O, Cejna M, Lammer J and Minar E: Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 354:1879–1888. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kipshidze N, Leon MB, Tsapenko M, Falotico R, Kopia GA and Moses J: Update on sirolimus drug-eluting stents. Curr Pharm Des. 10:337–348. 2004. View Article : Google Scholar : PubMed/NCBI
4	Schmieder GC, Richardson AI, Scott EC, Stokes GK, Meier GH 3rd and Panneton JM: Selective stenting in subintimal angioplasty: Analysis of primary stent outcomes. J Vasc Surg. 8:1175–1180. 2008. View Article : Google Scholar
5	Han B, Wang J, Wang B and Wang Z: Clinical analysis of endovascular treatment of patients with diabetic arteriosclerosis obliteration of lower extremity. Chinese Journal of General Surgery. 24:243–244. 2009.In Chinese.
6	Han B, Wang J, Wang B and Wang Z: Treatment of arteriosclerosis obliterans of lower extremity associated with thrombus formation. Clinical Medicine of China. 26:207–208. 2010.In Chinese.
7	Li YJ, Yan Guan and Wang ZL: Gene therapy restenosis. Chinese Journal of Arteriosclerosis. 9:77–81. 2001.In Chinese.
8	Maisel WH and Laskey WK: Cardiology patient page. Drug-eluting stents. Circulation. 115:e426–e427. 2007. View Article : Google Scholar : PubMed/NCBI
9	Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, et al: Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet. 370:937–948. 2007. View Article : Google Scholar : PubMed/NCBI
10	Gu WZ, Chen R, Brandwein S, McAlpine J and Burres N: Isolation, purification and characterization of immunosuppressive compounds from tripterygium: Triptolide and tripdiolide. Int J Immunopharmacol. 17:351–356. 1995. View Article : Google Scholar : PubMed/NCBI
11	Tao X and Lipsky PE: The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am. 26:29–50. 2000. View Article : Google Scholar : PubMed/NCBI
12	Chen BJ: Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb, Tripterygium wilfordii Hook F. Leuk Lymphoma. 42:253–265. 2001. View Article : Google Scholar : PubMed/NCBI
13	Dai C, Wang P, Zhang X and Zhu L: Triptolide PG490-88 combined with cyclosporin A induces immune tolerance in a rat renal allograft rejection model. Chinese Journal of Tissue Engineering Research. 15:861–864. 2011.In Chinese.
14	Lin J, Chen L, Lin Z and Zhao M: Inhibitory effect of triptolide on multiforme in vitro. J Int Med Res. 35:490–496. 2007. View Article : Google Scholar : PubMed/NCBI
15	Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S, Ross JA and Rosen GD: Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem. 276:2221–2227. 2001. View Article : Google Scholar
16	Tao R, Lu L, Zhang R, Hu J, Ni J and Shen W: Triptolide inhibits rat vascular smooth muscle cell proliferation and cell cycle progression via attenuation of ERK1/2 and Rb phosphoylation. Exp Mol Pathol. 90:137–142. 2011. View Article : Google Scholar
17	Fang W, Peng F, Yi T, Zhang C, Wan C, Lam CW and Yang X: Biological actity and safety of Tripterygium extract prepared by sodium carbonate extraction. Molecules. 17:11113–11123. 2012. View Article : Google Scholar : PubMed/NCBI
18	Zheng GH, Liu JP, Wang NS, Chen HY and Chu JF: Systematic review of Chinese herbal medicines for preventing in-stent coronary restenosis after percutaneous coronary intervention. Evid Based Complement Alternat Med. 2012:2534092012. View Article : Google Scholar : PubMed/NCBI
19	Shang D, Wang J and Bogen Z: Combination of Traditional Chinese and Western Medicing and Peripheral Vascular Diseases. People's Medical Publishing House Co., Ltd; Beijing: pp. 78–271. 2004
20	Monahan TS, Andersen ND, Panossian H, Kalish JA, Daniel S, Shrikhande GV, Ferran C and Logerfo FW: A novel function for cadherin 11/osteoblast-cadherin in vascular smooth muscle cells: Modulation of cell migration and proliferation. J Vasc Surg. 45:581–589. 2007. View Article : Google Scholar : PubMed/NCBI
21	Liu Z and Li C: Effect of intravascular stent surface modification on tunica intimal hyperplasia. Chinese Journal of Tissue Engineering Research. 14:4721–4724. 2010.In Chinese.
22	Lim KS, Jeong MH, Bac IH, Park JK, Park DS, Kim JM, Kim JH, Cho DL, Sim DS, Park KH, et al: Effect of atorvastatin-eluting stents in a rabbit iliac artery restenosis model. Chonnam Med J. 49:118–124. 2013. View Article : Google Scholar
23	Tsutsumi J, Ishikawa T, Nakano Y, Yoshimura M and Mutoh M: Long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement following rotablation for severely calcified lesions: A retrospective nonrandomized study. Cardiovasc Interv Ther. 30:29–37. 2015. View Article : Google Scholar
24	Remkes WS, Somi S, Roolvink V, Rasoul S, Ottervanger JP, Gosselink AT, Hoorntje JC, Dambrink JH, de Boer MJ, Suryapranata H, et al: Direct drug-eluting stenting to reduce stent restenosis: A randomized comparison of direct stent implantation to conventional stenting with pre-dilation or provisional stenting in elective PCI patients. JACC Cardiovasc Interven. 7:751–758. 2014. View Article : Google Scholar
25	Wan L, Liu J, Huang CB, Wang Y, Lei L, Liu L, Cheng YY and Feng YX: Effect of tripterygium glycosides on pulmonary function in adjuvant arthritis rats. J Chin Med Assoc. 76:715–723. 2013.In Chinese. View Article : Google Scholar : PubMed/NCBI
26	Wan L and Liu J: Changes of CD4(+) CD25(+) regulatory T cells, FoxP3 in adjuvant arthritis rats with damage of pulmonary function and effects of tripterygium glycosides tablets. Int J Rheumatol. 2012:3484502012.